High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
2024 · Journal of Thoracic Oncology · 29 citations
https://doi.org/10.1016/j.jtho.2024.09.1385
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
68
Citations
5
h-index
1
i10-index
Yingxi Wu is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & RNA modifications and cancer. The author has an h-index of 5, co-authored 12 publications.
https://doi.org/10.1016/j.jtho.2024.09.1385
https://doi.org/10.1177/15330338231168466
https://doi.org/10.1186/s12885-025-14313-7
Click to start Chat